Literature DB >> 11709337

Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.

M Takei1, H Fukuda, R Kishii, M Hosaka.   

Abstract

The antibacterial activities and target inhibition of 15 quinolones against grlA and gyrA mutant strains were studied. The strains were obtained from wild-type Staphylococcus aureus MS5935 by selection with norfloxacin and nadifloxacin, respectively. The antibacterial activities of most quinolones against both mutant strains were lower than those against the wild-type strain. The ratios of MICs for the gyrA mutant strain to those for the grlA mutant strain (MIC ratio) varied from 0.125 to 4. The ratios of 50% inhibitory concentrations (IC(50)s) of quinolones against topoisomerase IV to those against DNA gyrase (IC(50) ratios) also varied, from 0.177 to 5.52. A significant correlation between the MIC ratios and the IC(50) ratios was observed (r = 0.919; P < 0.001). These results suggest that the antibacterial activities of quinolones against the wild-type strain are involved not only in topoisomerase IV inhibition but also in DNA gyrase inhibition and that the target preference in the wild-type strain can be anticipated by the MIC ratios. Based on the MIC ratios, the quinolones were classified into three categories. Type I quinolones (norfloxacin, enoxacin, fleroxacin, ciprofloxacin, lomefloxacin, trovafloxacin, grepafloxacin, ofloxacin, and levofloxacin) had MIC ratios of <1, type II quinolones (sparfloxacin and nadifloxacin) had MIC ratios of >1, and type III quinolones (gatifloxacin, pazufloxacin, moxifloxacin, and clinafloxacin) had MIC ratios of 1. Type I and type II quinolones seem to prefer topoisomerase IV and DNA gyrase, respectively. Type III quinolones seem to target both enzymes at nearly the same level in bacterial cells (a phenomenon known as the dual-targeting property), and their IC(50) ratios were approximately 2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709337      PMCID: PMC90866          DOI: 10.1128/AAC.45.12.3544-3547.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.

Authors:  Y Onodera; Y Uchida; M Tanaka; K Sato
Journal:  J Antimicrob Chemother       Date:  1999-10       Impact factor: 5.790

2.  Antimicrobial evaluation of nadifloxacin (OPC-7251), a new topical quinolone, in acne vulgaris.

Authors:  K Vogt; H Hahn; J Hermann; U F Haustein; U Blume; H Gollnick; C E Orfanos
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 3.  Roles of DNA topoisomerases in chromosomal replication and segregation.

Authors:  J L Nitiss
Journal:  Adv Pharmacol       Date:  1994

4.  Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.

Authors:  J Yamagishi; T Kojima; Y Oyamada; K Fujimoto; H Hattori; S Nakamura; M Inoue
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

7.  Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.

Authors:  L Ferrero; B Cameron; B Manse; D Lagneaux; J Crouzet; A Famechon; F Blanche
Journal:  Mol Microbiol       Date:  1994-08       Impact factor: 3.501

8.  Primary targets of fluoroquinolones in Streptococcus pneumoniae.

Authors:  H Fukuda; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

9.  Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus.

Authors:  S Hori; Y Ohshita; Y Utsui; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.

Authors:  L Ferrero; B Cameron; J Crouzet
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  31 in total

1.  Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.

Authors:  Masaya Takei; Hideyuki Fukuda; Ryuta Kishii; Youko Kadowaki; Yukiko Atobe; Masaki Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

2.  Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase.

Authors:  Steven Bellon; Jonathan D Parsons; Yunyi Wei; Koto Hayakawa; Lora L Swenson; Paul S Charifson; Judith A Lippke; Robert Aldape; Christian H Gross
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

3.  The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.

Authors:  Sachin S Bhagwat; Lakshmi A Mundkur; Shrikant V Gupte; Mahesh V Patel; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

4.  Bacterial cell killing mediated by topoisomerase I DNA cleavage activity.

Authors:  Bokun Cheng; Shikha Shukla; Sarinnapha Vasunilashorn; Somshuvra Mukhopadhyay; Yuk-Ching Tse-Dinh
Journal:  J Biol Chem       Date:  2005-09-13       Impact factor: 5.157

5.  Ozenoxacin: A novel topical antibiotic.

Authors:  Parvathy Santhosh; Mithun Harold Thomas
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jan-Feb       Impact factor: 2.545

6.  Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.

Authors:  Xiao-Su Pan; Penelope J Hamlyn; Raquel Talens-Visconti; Fabiana L Alovero; Ruben H Manzo; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  In vitro activity of the new quinolone WCK 771 against staphylococci.

Authors:  Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Mahesh V Patel; Shrikant V Gupte; Sachin S Bhagwat; Noel J De Souza; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

8.  Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.

Authors:  Nadezhda German; Muhammad Malik; Jonathan D Rosen; Karl Drlica; Robert J Kerns
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

9.  Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium.

Authors:  Yuko Yamaguchi; Masaya Takei; Ryuta Kishii; Mitsuru Yasuda; Takashi Deguchi
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

10.  Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus.

Authors:  Dilek Ince; Xiamei Zhang; L Christine Silver; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.